Huntington’s Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

Huntington's Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Huntington’s Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The treatment for Huntington’s disease is complex as there exists no cure for Huntington’s disease, and there are no treatments known to slow or reverse its process. The current treatment available is symptoms specific, with the treatment goal to slow down the course of the disease and help affected people function for as long and as comfortably as possible.

To improve the treatment scenarios, companies like Prilenia Therapeutics [Pridopidine (ACR-16; Huntexil)], Neurocrine Biosciences [Ingrezza (Valbenazine/NBI-98854)], Annexon Biosciences [ANX005], SOM Biotech [SOM3355/Bevantolol], Vaccinex [Pepinemab (VX15/2503)], SAGE Therapeutics [SAGE-718], UniQure Biopharma [AMT-130 (intra-striatal rAAV5-miHTT)], and others are involved in developing therapies for Huntington’s Disease.

Huntington’s Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Huntington’s Disease Market. 

The Huntington’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Huntington's Disease Pipeline Analysis

Huntington’s Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Huntington’s Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Huntington’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Huntington’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravitreal 

  • Subretinal

  • Topical 


Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides 

  • Polymer 

  • Small molecule

  • Gene therapy


Mechanism of Action (MOA) of the Emerging Pipeline Therapies

  • RNA interference

  • Complement C1 inhibitors

  • NMDA receptor modulators

  • Dopamine D2 receptor antagonists

  • Vesicular monoamine transporter 2 inhibitors

  • HDAC6 protein inhibitors

  • Neuron modulators

  • Gene expression regulation modulators

  • Survival of motor neuron 2 protein modulators


Learn How the Ongoing Clinical & Commercial Activities will Affect the Huntington’s Disease Therapeutic Segment @

Huntington’s Disease Therapeutics Landscape

The Huntington’s Disease therapeutics market is anticipated to evolve immensely in the coming years owing to the entry of innovative emerging therapies, rising prevalence, increasing initiatives for R&D, and the advent of genetic testing.

There are approx. 50+ key companies developing therapies for Huntington’s Disease. Currently, Ionis Pharmaceuticals is leading the therapeutics market with its Huntington’s Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Huntington’s Disease Therapeutics Market Include:

Amsterdam Molecular Therapeutics, Annexon, Celon Pharma, Chong Kun Dang Pharmaceutical, EIP Pharma, Hope Biosciences, Ionis Pharmaceuticals, Luye Pharma Group, Medesis Pharma, Neurimmune Therapeutics, Neurocrine Biosciences, Novartis, Prilenia Therapeutics, PTC Therapeutics, Retrotope, Sage Therapeutics, Sangamo Therapeutics, SOLA Biosciences, Spark therapeutics, Stealth BioTherapeutics, UniQure Biopharma, Vaccinex, Wave Life Sciences, and many others.

Huntington’s Disease Drugs Covered in the Report Include:

  • ANX005: Annexon

  • CKD-504: Chong Kun Dang Pharmaceutical

  • Huntington’s Disease therapy: Spark therapeutics

  • NP03: Medesis Pharma

  • Pridopidine: Prilenia Therapeutics

  • rAAV5-miHTT: UniQure Biopharma

  • SAGE-718: Sage Therapeutics

  • TAK-686: Sangamo Therapeutics

  • Tominersen: Ionis Pharmaceuticals

  • Valbenazine: Neurocrine Biosciences

  • WVE003: Wave Life Sciences

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Huntington’s Disease Current Treatment Patterns

4. Huntington’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Huntington’s Disease Late Stage Products (Phase-III)

7. Huntington’s Disease Mid-Stage Products (Phase-II)

8. Huntington’s Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Huntington’s Disease Discontinued Products

13. Huntington’s Disease Product Profiles

14. Key Companies in the Huntington’s Disease Market

15. Key Products in the Huntington’s Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Huntington’s Disease Unmet Needs

18. Huntington’s Disease Future Perspectives

19. Huntington’s Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States